A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin
研究单位：[1]Eli Lilly and Company[2]Alliance Research Institute - Canoga Park,Canoga Park,California,United States,91304[3]Ark Clinical Research,Long Beach,California,United States,90815[4]Collaborative Neuroscience Research, LLC,Los Alamitos,California,United States,90720[5]Wolverine Clinical Trials,Santa Ana,California,United States,92705[6]CMR of Greater New Haven,Hamden,Connecticut,United States,06517[7]Institute of Endocrinology Diabetes, Health & Hormone,Stockbridge,Georgia,United States,30281[8]Elite Clinical Trials,Rexburg,Idaho,United States,83440[9]Accellacare - DuPage,Lombard,Illinois,United States,60148[10]Tandem Clinical Research,Marrero,Louisiana,United States,70072[11]St. Vincent Healthcare,Billings,Montana,United States,59101[12]Albuquerque Clinical Trials, Inc.,Albuquerque,New Mexico,United States,87102[13]Accellacare - Winston-Salem,Winston-Salem,North Carolina,United States,27103[14]Alliance for Multispecialty Research, LLC,Norman,Oklahoma,United States,73069[15]Essential Medical Research,Tulsa,Oklahoma,United States,74137[16]Accellacare - Mt Pleasant,Mount Pleasant,South Carolina,United States,29464[17]Accellacare, US Inc., d/b/a Accellacare of Knoxville,Jefferson City,Tennessee,United States,37760[18]Dallas Diabetes Research Center,Dallas,Texas,United States,75230[19]Juno Research,Houston,Texas,United States,77040[20]Consano Clinical Research, LLC,Shavano Park,Texas,United States,78231[21]The Second People''s Hospital of Hefei,Hefei,Anhui,China,230011[22]The Fourth Hospital of Harbin Medical University,Harbin,Heilongjiang,China,150001[23]The First Affiliated Hospital of Nanyang Medical College,Nanyang,Henan,China,473007[24]The Second Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450014[25]Nanjing First Hospital,Nanjing,Jiangsu,China,210006[26]The Second Affiliated Hospital of Nanjing Medical University,Nanjing,Jiangsu,China,210011[27]The First Affiliated Hospital of Soochow University,Suzhou,Jiangsu,China,215006[28]Affiliated Hospital of Jiangsu University,Zhenjiang,Jiangsu,China,212000[29]Jinan Central Hospital,Jinan,Shandong,China,250013[30]Shanghai Sixth People''s Hospital,Shanghai,Shanghai,China[31]First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650032[32]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,China,325000[33]CRS Clinical Research Services Mannheim,Mannheim,Baden-Württemberg,Germany,68167[34]Diabetologische Schwerpunktpraxis Dr. Staudenmeyer & Dr. Schiwietz,Lingen,Niedersachsen,Germany,49808[35]Diabetes- und Stoffwechselpraxis Bochum,Bochum,Nordrhein-Westfalen,Germany,44869[36]InnoDiab Forschung Gmbh,Essen,Nordrhein-Westfalen,Germany,45136[37]Medizentrum Essen Borbeck,Essen,Nordrhein-Westfalen,Germany,45355[38]Zentrum fur klinische Forschung - Köln,Köln,Nordrhein-Westfalen,Germany,51069[39]Institut für Diabetesforschung GmbH Münster,Münster,Nordrhein-Westfalen,Germany,48145[40]Diabetologikum Ludwigshafen/Die Praxis am Ludwigsplatz,Ludwigshafen am Rhein,Rheinland-Pfalz,Germany,67059[41]Diabetologische Schwerpunktpraxis und Praxis für Allgemeinmedizin Dr. Veronika Wenzl-Bauer null Josef Wenzl,Rehlingen,Saarland,Germany,66780[42]Zentrum für klinische Studien,St.Ingbert,Saarland,Germany,66386[43]RED-Institut GmbH,Oldenburg,Schleswig-Holstein,Germany,23758[44]Diabetes Zentrum Wilhelmsburg,Hamburg,Germany,21109[45]Cryptex Investigación Clínica S.A. de C.V.,Cuauhtémoc,Distrito Federal,Mexico,06100[46]ProcliniQ Investigación Clínica SA de CV,Mexico City,Distrito Federal,Mexico,14050[47]Grupo Ollin Care,Pachuca,Hidalgo,Mexico,42000[48]Instituto Jalisciense de Investigacion en Diabetes y Obesidad,Guadalajara,Jalisco,Mexico,44600[49]Instituto de Diabetes, Obesidad y Nutricion,Cuernavaca,Morelos,Mexico,62250[50]Cardiolink Clin Trials,Monterrey,Nuevo León,Mexico,64060[51]Clínica García Flores SC,Monterrey,Nuevo León,M
研究目的：
The main purpose of this study is to assess the safety and efficacy of orforglipron compared with dapagliflozin in improving blood sugar control in participants with type 2 diabetes (T2D) with inadequate glycemic control using metformin. The study will last approximately 46 weeks.
